Skip to main content
OpenTrials
Completed

NCT Number: NCT02424578

Study of Diclofenac Capsules to Treat Pain Following Surgery in Children Ages 6 to <17 Years of Age

The purposes of this study are to evaluate the safety and tolerability and to model the single-dose pharmacokinetic profile of diclofenac capsules low dose and high dose in children ages 6 to <17 years experiencing mild to moderate acute postoperative pain.

Completed

Looking for future studies?

Notify Me

Key information

Age range

6 year–16 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Sheffield, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Body weight ≥18 kilograms.
  • Mild to moderate acute pain requiring treatment with analgesic medication.
  • Willing to have blood samples taken for PK sampling using an indwelling catheter.
  • Must be able to swallow capsules and can tolerate oral medication.
  • For females: is not of reproductive potential (defined as premenarchal) or is practicing an acceptable method of birth control

Exclusion criteria

  • Severe acute pain
  • Chronic analgesic or glucocorticoid use for any condition within 6 months before dosing with study drug.
  • Emergency surgery
  • History of allergic reaction, hypersensitivity, or clinically significant intolerance to diclofenac, aspirin, codeine, acetaminophen, or any NSAID
  • History of peptic ulcer disease or a GI event (eg, perforation, obstruction, or bleed) within 6 months before screening
  • Current use of any medication that may cause a clinically significant drug interaction when co-administered with diclofenac
  • Current use of any medication that might affect the pharmacokinetics of diclofenac
  • History of bleeding disorders .
  • Developmental delay or behavioral problems that would make it difficult to assess pain.
  • Impaired liver function
  • Clinically significant renal or cardiovascular disease
  • Any medical condition that compromises ability to swallow, absorb, metabolize, or excrete the study drug
  • Previously received any investigational product or device within 30 days before Screening or scheduled to receive an investigational device or another investigational drug (other than that in this study) during the course of this study.
  • Previous participation in this clinical study or currently taking diclofenac.

Treatment and study plan

Diclofenac Capsules low dose

Drug

Diclofenac Capsules high dose

Drug

Primary outcomes

  1. Plasma Concentration of Diclofenac

    Time frame: 0-6 hours after first dose of diclofenac

    The estimated typical value for clearance (tvCl) following a single diclofenac dose based on population pharmacokinetic (PopPK) modeling using sparse plasma concentration data in pediatric subjects.

Secondary outcomes

  1. Safety of Diclofenac Capsules Low Dose and High Dose as Assessed by the Incidence of Adverse Events From Baseline to Day 3 or Early Termination

    Time frame: Baseline to Day 3/Early Termination

Sponsors and collaborators

Lead sponsor

Iroko Pharmaceuticals, LLC

Industry

Registry information

Official study title

A Phase IIA, Open-Label, Safety and Pharmacokinetic Study of Diclofenac Capsules in Pediatric Subjects 6 to <17 Years of Age With Mild to Moderate Acute Postoperative Pain Following Elective Surgery

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Apr 23, 2015
Registry last updated
Jul 13, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.